A Shenzhen investor search becomes more useful when hardware development, frontier software, corporate deployment and commercial scale are treated as different funding jobs. This guide compares 15 provider families and makes the local, Greater Bay Area and wider China connections explicit.
Compare 15 provider families, including 5 documented local or regional routes. Start with the decision framework, use the comparison to screen candidates and save the evidence in the worksheet before you approach anyone.
Choose a Shenzhen funding route by technical and commercial milestone
| Your situation | Research first | Prepare or clarify |
|---|---|---|
| Early hardware or frontier technology | Compare SCGC, QF and relevant Vertex China or Linear strategies. | Show the technical result, prototype reliability and next customer or manufacturing test. |
| A China technology or healthcare opportunity | Research Qiming’s relevant vehicle and current founder route. | Its Hong Kong office is regional context, not a claimed Shenzhen office. |
| A functioning company preparing growth | Compare Legend’s growth lane with the appropriate wider venture strategy. | Separate demonstrated commercial operations from projected scale. |
| Enterprise cloud or a founder programme | Compare Eminence for product fit or MiraclePlus for its actual cohort and investment terms. | Do not treat a software specialist and an accelerator as the same financing mechanism. |
Choose a small first wave you can research properly. Record one reason for fit, one relevant proof point and the next unanswered question for each investor. Move a name out of the active queue when the stage, sector or geographic conditions do not fit.
Compare 15 local and wider investor routes
The connection column distinguishes a documented city or regional route from a wider mandate. It does not imply that every provider has an office here. Initial investment stages and follow-on support are different. This selective list is unranked; each provider family counts once.
| Investor or network | Connection | Entry-stage distinction | Company focus |
|---|---|---|---|
| Vertex Ventures China | Local / regional: China team with Beijing, Shanghai and Shenzhen offices | Early-stage investments; fund-specific | Technology; advanced manufacturing; biomedicine |
| Qiming Venture Partners | Local / regional: Hong Kong regional office in the Greater Bay Area; China investment strategies | Early and growth stages | Technology and healthcare innovation |
| Linear Capital | Wider route: China-linked technology investor with international examples | Angel through Series A | AI software and hardware; science and manufacturing |
| Jingwei Venture Capital | Wider route: China-focused strategy in its Chinese-language overview | Early and early-growth stages | Software; technology; advanced manufacturing; consumer |
| Soul Capital | Wider route: Explicit China-focused early-stage strategy | Early stage | Technology startups |
| Lighthouse Yuanzhan Capital | Wider route: China-based manager with China and US startup activity | Early stage | Technology products and commercialization |
| Long Venture Partners | Wider route: Published China and US investment focus | Early stage | Fintech; enterprise; consumer internet; AI and data |
| Lingfeng Capital | Wider route: Greater China and ASEAN focus with other selective exposure | Early through growth; vehicle-specific | Digital finance; industrial technology; AI and data |
| Next Capital | Wider route: Published founder-investment history includes China's technology market | First investment and early stage | Technology startups; company-specific |
| Eminence Ventures | Wider route: Published China enterprise-cloud focus | Early stage | Enterprise software and cloud computing |
| EdgeVentures | Wider route: China-connected manager; verify the current fund's geographic remit | Angel through Series A emphasis; later participation varies | Internet; technology; consumer services |
| MiraclePlus | Wider route: Early-stage accelerator for startups in China | Early-stage cohort; terms and timing may change | Startup and technology companies |
| Legend Capital | Local / regional: Shenzhen office | Early venture and growth strategies differ | Technology; enterprise; manufacturing; health and other themes |
| Shenzhen Capital Group | Local / regional: Shenzhen base; nationwide investment network | Early and growth VC/PE strategies differ | Information technology; advanced manufacturing; healthcare; materials; energy |
| QF Capital / 启赋资本 | Local / regional: Shenzhen office; Sanya headquarters | Angel and early VC emphasis | Information technology; advanced manufacturing; life sciences; new materials |
Separate Shenzhen offices from the wider Greater Bay Area
Vertex China, Legend and QF publish Shenzhen connections, and SCGC is rooted in the city. Qiming’s current contact page lists Hong Kong in the wider Greater Bay Area, not Shenzhen. Those are different kinds of regional access and are labelled accordingly in the table.
Wider China investors can still be useful when the company matches their current mandate. The China investor guide remains the national overview. Here, record whether the connection is a local office, a regional office or wider investment eligibility. Do not turn all three into the same city-based claim.
A manufacturing milestone is not the same as a software launch
A Shenzhen hardware team should explain what works, which customer has tested it and what remains uncertain about reliability, production and deployment. A software team should explain product usage, buyer value and the next commercial test. Frontier-technology investors may need both sets of evidence.
Linear’s current thesis distinguishes AI applications, hardware, science and manufacturing. SCGC’s current overview separates direct venture activity from its wider asset-management platform. These are useful filters, not a guarantee that a particular vehicle has available capital for the company.
Use the project pitch channel, not a fund-capital enquiry
QF’s Contact page separates project cooperation from fund-capital cooperation. Qiming publishes a BP submission route distinct from media and general enquiries. A founder seeking company investment should use the appropriate channel and provide a concise description of the business, evidence, round and fit.
USD and RMB vehicles can have different company and process requirements. Confirm the relevant vehicle with the firm and appropriate advisers rather than infer eligibility from a portfolio company. Keep the information general and avoid sharing confidential material before understanding the actual recipient and process.
15 investors and networks to research
1. Vertex Ventures China
China venture fund team. Vertex China lists a Shenzhen office within an independent China investment team. A Shenzhen founder should explain the technology, current company stage and intended operating market. Other Vertex regional teams are not additional counts or the same eligibility screen.
Approach: Official investment information. Official Vertex Ventures China information.
2. Qiming Venture Partners
Venture investment manager. Qiming’s current contact page lists a Hong Kong office in the wider Greater Bay Area, not a Shenzhen office. Its China technology and healthcare strategies provide a regional research lane. Use the published BP submission route and confirm the relevant vehicle and initial stage.
Approach: Use BP submission on the official Contact page. Official Qiming Venture Partners information. Additional criteria or geographic context.
3. Linear Capital
Frontier-technology venture investor. Linear’s current frontier-technology thesis covers AI software, hardware, science and manufacturing, with angel-to-Series-A entry. A Shenzhen hardware team should show the technical result and a practical production or customer milestone. Its wider China strategy is not a claim of a Shenzhen office.
Approach: Official investment information. Official Linear Capital information.
4. Jingwei Venture Capital
China venture investment manager. Jingwei’s current China identity should not be double-counted with the legacy Matrix China name. A Shenzhen software or advanced-manufacturing team should show the actual product and early-growth evidence. Choose the relevant current team and vehicle.
Approach: Official investment information. Official Jingwei Venture Capital information.
5. Soul Capital
Early-stage venture investor. Soul’s China-focused early-stage technology strategy provides a wider comparison for a Shenzhen company. Prepare the actual product insight and evidence. Confirm the current vehicle and founder route instead of treating a historical investment as an open invitation.
Approach: Official investment information. Official Soul Capital information.
6. Lighthouse Yuanzhan Capital
Early-stage venture investor. Lighthouse’s early-technology and commercialization focus is a wider route for a Shenzhen team. Connect the technical result to a usable product and next customer test. Its China/US activity does not establish a Shenzhen office.
Approach: Official investment information. Official Lighthouse Yuanzhan Capital information.
7. Long Venture Partners
Cross-border venture firm. Long’s China–US early-stage strategy is useful only when the Shenzhen company has a real reason for that cross-border connection. Explain the first customer market and current evidence. A general overseas ambition is not a demonstrated advantage.
Approach: Official investment information. Official Long Venture Partners information.
8. Lingfeng Capital
Regional technology venture manager. Lingfeng’s Greater China and ASEAN technology strategies include digital finance and industrial technology. A Shenzhen founder should identify the current vehicle and initial stage. Separate a corporate commercial relationship from the equity case.
Approach: Official investment information. Official Lingfeng Capital information.
9. Next Capital
Early-stage venture investor. Next’s early-company proposition provides a wider China research option for a Shenzhen founder. Explain the first product, team and learning. Confirm the current strategy rather than relying only on the manager’s historical first-investor examples.
Approach: Official investment information. Official Next Capital information.
10. Eminence Ventures
Enterprise-cloud venture firm. Eminence belongs in the enterprise-cloud and software lane. A Shenzhen team should explain the business buyer, deployment and current usage. It is not interchangeable with a physical-product investor merely because both discuss technology.
Approach: Official investment information. Official Eminence Ventures information.
11. EdgeVentures
Venture investment firm. Edge’s angel-to-Series-A emphasis provides a wider early technology comparison. A Shenzhen founder should establish the actual current fund and operating-market fit. Later participation in a company is not proof of the same first-entry stage.
Approach: Official investment information. Official EdgeVentures information.
12. MiraclePlus
Investment-backed accelerator. MiraclePlus combines early investment with a China founder accelerator. A Shenzhen team should assess selection, participation and current financing terms together. Community resources and cohort acceptance should not be represented as an unconditional investment.
Approach: Official accelerator information. Official MiraclePlus information.
13. Legend Capital
Venture and growth private-equity manager. Legend’s current site lists a Shenzhen office and separates early venture from growth private equity. A Shenzhen founder should identify the actual company stage, sector and team. Fundraising into a fund and a company seeking investment are different enquiries.
Approach: Use official team/contact information; do not assume an LP contact is a company pitch route. Official Legend Capital information.
14. Shenzhen Capital Group
Venture and private-capital manager. SCGC’s current overview emphasizes venture capital and hard technology across China. A Shenzhen team should choose direct-company equity rather than its fund-of-funds, public-market or other asset activities. Government-related fund commitments are not extra startup investors in this list.
Approach: Use the current official team/contact route. Official Shenzhen Capital Group information. Additional criteria or geographic context.
15. QF Capital / 启赋资本
Early-stage technology venture manager. QF’s current overview emphasizes angel and early venture investment in technology-led industries. Its contact page lists a Shenzhen office and separates project cooperation from fund-capital cooperation. A Shenzhen founder should use the project route and explain the actual technical and commercial milestone.
Approach: Use the project-cooperation BP route on Contact. Official QF Capital / 启赋资本 information. Additional criteria or geographic context.
A Shenzhen robotics team chooses the next financing evidence
Fictional worked example. A fictional Shenzhen robotics team has a working prototype, one trial site and a plan for a pilot batch. It has no recurring revenue and no signed investment. The assumed next round funds reliability and commercial validation, not mass production at proven scale.
| Candidate | Next action | Why it changes the decision |
|---|---|---|
| SCGC / QF / Vertex China | Research the relevant early technology criteria and team. | The prototype and next validation milestone provide a specific company brief. |
| Linear Capital | Explain the frontier-hardware result and real-world application. | An AI label alone is not technical differentiation. |
| Qiming | Identify the correct technology vehicle and BP route. | Regional Hong Kong presence does not become an invented Shenzhen office. |
| Legend growth strategy | Defer unless the operating evidence fits the growth lane. | A prototype is not a mature commercial business. |
The aim is a more coherent queue, not the largest possible one. Connect the proposed round with an achievable milestone using the round-size planning worksheet.
Build your Shenzhen investor-fit worksheet
Use one card for each provider and strategy. It works in a document, spreadsheet or your Finta research notes. Keep facts, expectations and questions in separate fields.
INVESTOR FIT CARD: SHENZHEN
Company, current evidence and next funding milestone: [authorised facts]
Shenzhen / Greater Bay Area / wider China connection: label each precisely
Company, operating market and intended current investment vehicle
Prototype reliability, production and real customer evidence
Initial investment versus follow-on stage: current source
Founder BP/project channel versus LP/fund-capital enquiry
Investor and specific vehicle: [current name; avoid rebrand duplicates]
Official stage, sector and geographic criteria: [URL; date]
Fit evidence: [what matches; not just a portfolio resemblance]
Mismatch or open question: [the unresolved issue]
Approach route: [founder form / network selection / general enquiry]
Relationship context: [known person; permission to ask; or public route]
Lead/co-investment status: [unknown / conditional / confirmed]
Owner, next action and follow-up date: [person; action; date]Bring the shortlist into Finta to keep investor research, relationship context and follow-up connected. Aurora can help organise the context and prepare a next move for your review. You stay in control of the approach and information shared.
Review your shortlist with Aurora, Claude or Codex
Paste the prompt with the public sources and company information you are authorised to use. Check its output against the sources before acting.
Help me research investor fit for a Shenzhen startup.
Company, location, current evidence and funding milestone: [authorised facts]
Candidates and official sources: [names, URLs and research dates]
Separate local offices, regional operating requirements and wider investment eligibility.
Check the specific vehicle, initial stage, sector, company conditions and public approach route.
Keep university programmes, angel networks, direct equity, grants and commercial partnerships distinct.
Count each manager or rebrand once. Do not assume a portfolio investment proves current eligibility.
Return a table: source, fit evidence, mismatch, unknown, next question and owner.
Flag missing or contradictory evidence instead of filling gaps.
Suggest a short first research wave and explain exclusions.
Do not contact anyone, submit forms or share confidential information.Keep the wider fundraising process connected with the pre-seed guide, Seed Fundraising Comprehensive Guide and investor-prospecting workflow. For national coverage, see the China investor guide.
Methodology and research date
By Finta Editorial Team. Official investor, public-institution and company materials reviewed November 13, 2026, with source-dated prior research used for discovery. 15 provider families are included: 5 documented local or regional routes and 10 wider mandates. Angel networks are identified as networks, not pooled funds. Company-building and strategic investment routes are labelled separately.
Startup Genome’s 2026 Emerging Ecosystems ranking informed city selection; it is not an investor ranking or endorsement. Current official materials support the profiles. A published thesis is not a promise of available capital, current intake or an investment outcome. Confirm open questions directly.
Not counted or kept separate:
- Qiming is labelled a Hong Kong regional connection, not a Shenzhen office.
- SCGC direct venture, fund-of-funds and other asset strategies are not additional independent investors.
- Providers with unresolved website/certificate or stale identity evidence are not inserted to inflate the count.
General information, not personalised financial, legal or tax advice. Programme and company criteria are research filters, not an eligibility ruling. The cover is an editorial ecosystem illustration, not a map of investor offices or actual financing flows.